Physician profile
Izabela Antic
NPI 1295296945
$4,619.55
in general payments reported to CMS, 2019-2025
15 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.25 · 2022: $538 · 2023: $1,742 · 2024: $2,177 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,966 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,965.91 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,100.14 | 2022-2024 | |
| Amgen INC. | $1,035.91 | 2022-2024 | Enbrel, Evenity, Tavneos |
| Abbvie INC. | $657.43 | 2022-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $455.58 | 2024-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $259.17 | 2023-2024 | Cimzia |
| Janssen Scientific Affairs, LLC | $235.00 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.32 | 2022-2024 | Ofev |
| Aurinia Pharma U.S., INC. | $160.18 | 2023-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $140.04 | 2023 | Nucala, Benlysta |
| Horizon Therapeutics Plc | $119.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $97.34 | 2023-2024 | Saphnelo |
| Fresenius Kabi USA, LLC | $63.37 | 2023 | Idacio |
| Pfizer INC. | $51.88 | 2023-2024 | |
| Lilly USA, LLC | $42.33 | 2020-2024 | Taltz |
| Sobi, INC | $19.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Izabela Antic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.